Emcure Pharmaceuticals Limited has informed the Exchange about General Updates
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
At Emcure Pharmaceuticals' 44th Annual General Meeting held on August 28, 2025, shareholders approved two key items. First, Dr. Mukund Gurjar (DIN: 00026843) was re-appointed as a Whole-time Director for another one-year term starting August 28, 2025. Second, M/s. SVD & Associates, Company Secretaries, was appointed as the Secretarial Auditor of the company for five consecutive years beginning FY 2025-26. The voting results were submitted to both NSE and BSE on August 29, 2025.
This is a routine governance update with no material impact on shareholders — a re-appointment of an existing director and a new secretarial auditor appointment signal continuity and compliance rather than any meaningful change to the business or stock.